Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
756 stopped studies mapped to Acute Leukemia and descendants · 89% state a reason
Over the 756 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children… | Phase 2 | terminated | Aug 31, 2015 | Children's Mercy Hospital Kansas City | Funding source discontinued | Funding |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid… | Phase 2 | terminated | Dec 18, 2015 | Mayo Clinic | not stated | Not stated |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | terminated | Sep 14, 2005 | Masonic Cancer Center, University of Minnesota | Accrual Goal Met | Enrollment / accrual |
| NCT02477787 | Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk…(DNKI-4) | Phase 2 | terminated | Jun 23, 2015 | Asan Medical Center | upon recommendation from the Data Monitoring Committee | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children… | Phase 1 / Phase 2 | terminated | May 14, 2013 | Janssen Research & Development, LLC | EMA/PDCO acknowledged that available results from this study do not support further clinical… | Other (stated, no rule matched) |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a… | Phase 1 | terminated | Nov 8, 2018 | Dana-Farber Cancer Institute | Sponsor Decision | Sponsor / business decision |
| NCT01214655 | A Study for Patients With Acute Leukemia | Phase 1 | terminated | Oct 5, 2010 | Eli Lilly and Company | Primary objective has been met in the absence of clinically meaningful remissions | Other (stated, no rule matched) |
| NCT03752138 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid… | Phase 1 | withdrawn | Nov 23, 2018 | M.D. Anderson Cancer Center | The supporting pharamceutical company elected not to pursue this study at this time. | Sponsor / business decision |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk… | Phase 1 | terminated | Apr 25, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study drug supply expired and could not be renewed. | Drug supply |
| NCT03291353 | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute… | Early Phase 1 | withdrawn | Sep 25, 2017 | Michael Boyiadzis | This study has closed due to slow accrual. | Enrollment / accrual |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage… | Phase 1 | suspended | Nov 1, 2013 | National University Health System, Singapore | Suspended for an interim review of (CAR) CD19 research strategy for the treatment of CD19 positive… | Sponsor / business decision |
| NCT02826642 | A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia | Phase 1 | withdrawn | Jul 11, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00808080 | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell…(AMLCTL) | Phase 1 / Phase 2 | terminated | Dec 15, 2008 | Thomas A. Lane, MD | lack of accrual | Enrollment / accrual |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jan 8, 2014 | Steven E. Coutre | Regulatory | Other (stated, no rule matched) |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | Phase 2 | terminated | Dec 21, 2017 | St. Petersburg State Pavlov Medical University | Unexpected toxicity | Safety / toxicity |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or… | Phase 2 | terminated | Aug 10, 2015 | St. Jude Children's Research Hospital | Due to slow accrual | Enrollment / accrual |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or… | Phase 1 / Phase 2 | terminated | Apr 16, 2015 | Spirita Oncology, LLC | Insufficient efficacy in Phase 1 dose-escalation portion of study | Efficacy / futility |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal… | Phase 2 | withdrawn | Jun 15, 2017 | Matinas BioPharma Nanotechnologies, Inc. | Protocol redundancy | Other (stated, no rule matched) |
| NCT03705858 | Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | Phase 1 | withdrawn | Oct 15, 2018 | Joseph Jurcic | Due to difficulty in finalizing the contract | Other (stated, no rule matched) |
| NCT01701323 | Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients… | Phase 1 | terminated | Oct 5, 2012 | Nohla Therapeutics, Inc. | not stated | Not stated |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients… | Phase 1 / Phase 2 | withdrawn | Oct 9, 2018 | Memorial Sloan Kettering Cancer Center | Study sponsor discontinued support | Other (stated, no rule matched) |
| NCT00928200 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND… | Phase 1 | terminated | Jun 25, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Study was terminated due to lack of accrual. | Enrollment / accrual |
| NCT02989675 | SugarFACT - Sugar Requirements For African Children Trial | N/A | terminated | Dec 12, 2016 | Helena Hildenwall | not stated | Not stated |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Phase 1 | terminated | May 8, 2013 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk… | Phase 1 / Phase 2 | terminated | Apr 9, 2008 | Viron Therapeutics Inc | not stated | Not stated |
| NCT02412475 | Epigenetic Reprogramming in Relapse AML | Phase 1 | terminated | Apr 9, 2015 | Michael Burke | We opened a competing study with the TACL consortium | Other (stated, no rule matched) |
| NCT02614560 | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem… | Phase 1 / Phase 2 | terminated | Nov 25, 2015 | Seagen Inc. | not stated | Not stated |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | Phase 1 | terminated | Feb 17, 2016 | Plexxikon | Business Decision | Sponsor / business decision |
| NCT01479582 | Providing Access to Cord Blood Units for Transplants | Phase 2 | withdrawn | Nov 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory… | Phase 1 | terminated | May 27, 2015 | Janssen Research & Development, LLC | Recent advances in the treatment of B cell malignancies resulting in new treatments being approved… | Other (stated, no rule matched) |
| NCT02785900 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older…(CASCADE) | Phase 3 | terminated | May 30, 2016 | Seagen Inc. | Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm… | Safety / toxicity |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT02676323 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid… | Phase 1 | terminated | Feb 8, 2016 | St. Jude Children's Research Hospital | Slow accrual | Enrollment / accrual |
| NCT02587871 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute… | Phase 2 | withdrawn | Oct 27, 2015 | University of Southern California | PI decided not to pursue study | Other (stated, no rule matched) |
| NCT03365661 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | Phase 2 | withdrawn | Dec 7, 2017 | Masonic Cancer Center, University of Minnesota | Sponsor halted study. | Other (stated, no rule matched) |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | Phase 1 / Phase 2 | terminated | Aug 15, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01904643 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or… | Phase 1 | terminated | Jul 22, 2013 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00038870 | Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes | N/A | withdrawn | Jun 7, 2002 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT02992860 | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED…(SAMBA) | Phase 2 | terminated | Dec 14, 2016 | GWT-TUD GmbH | Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with… | Enrollment / accrual |
| NCT03207334 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | Phase 2 | withdrawn | Jul 2, 2017 | University of Florida | Insufficient funding | Funding |
| NCT01846624 | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid… | Phase 2 | terminated | May 3, 2013 | David Iberri | Accrual factor | Enrollment / accrual |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00907517 | Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute… | Phase 1 | terminated | May 22, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01451437 | Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute… | Phase 1 | terminated | Oct 13, 2011 | Merck Sharp & Dohme LLC | The study was terminated early due to business reasons. | Sponsor / business decision |
| NCT02632903 | Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in… | Phase 2 | withdrawn | Dec 17, 2015 | Children's Hospital of Eastern Ontario | While the clinical need for and the scientific merit remain valid, this regulated drug trial was… | Funding |
| NCT01588951 | Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | Phase 2 / Phase 3 | terminated | May 1, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 13, 2019source: clinicaltrials